OC 60.2 - Emicizumab Treatment is Efficacious and Well Tolerated Long Term in Persons with Haemophilia A (PwHA) with or without FVIII Inhibitors: Pooled Data from Four HAVEN Studies

  • Presentation
Oral Communication Session
© 2021 International Society on Thrombosis and Haemostasis, Inc. All rights reserved.
Meeting: ISTH 2019 Congress
Presenter: M. Callaghan
Presentation Date: July 9, 2019
Abstract #: OC 60.2 / 358

Disclaimer

This content was selected by and is provided to you courtesy of Your Company.
© 2021 International Society on Thrombosis and Haemostasis, Inc. All rights reserved.

This content is provided for informational purposes and personal use only, and is not intended to provide medical advice, diagnosis, or treatment or for commercial use. The ideas and opinions expressed herein do not necessarily reflect those of the International Society on Thrombosis and Haemostasis, Inc. The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.

Site provided by Springer Healthcare Limited. Part of the Springer Nature Group.

Selected Presentation from the ISTH Congress (For Demo Purposes Only)

Emicizumab Treatment is Efficacious and Well Tolerated Long Term in Persons with Haemophilia A (PwHA) with or without FVIII Inhibitors: Pooled Data from Four HAVEN Studies

Content Available: Presentation Video

By accessing this collection you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
Please note, this is for demo purposes only. Your data will not be collected.
Copyright: © 2021 International Society on Thrombosis and Haemostasis, Inc. All rights reserved.